Sitemap | Feedback

Advanced search

Journal of Case Reports

Primary-Inoculation Tuberculosis of Keloid Presenting as Cold Abscess

bentelan torrino

bentelan torrino open

prednisolon kol

prednisolon kur hk.onkyo.com

Supriya Panda, N K Panigrahi¹

From the Department of Microbiology, Maharajah’s Institute of Medical Sciences, Nellimarla. Vizianagaram. Andhra Pradesh and Department of Cardiology¹, Heart and Kidney Centre, Apollo Hospital, Visakhapatanam, Andhra Pradesh, India.

Corresponding Author:
Dr. Supriya Panda Email: drsupriyapanda@gmail.com

Received: 27 MAY 2013

Accepted: 24-JUN-2013

Published Online: 30-JUL-2013

DOI:	http://dx.doi.org/10.17659/01.2013.0057

Abstract

Primary-inoculation tuberculosis of the skin resulting from direct inoculation is a rare disease first described by Laennec. Mycobacterium cannot penetrate intact skin and requires a breach in the skin to enter. The disease usually remains localized in those patients with acquired immunity from previous infection with Mycobacterium tuberculosis. The patient will develop a papule or nodule that will eventually ulcerate 2 or 3 weeks after the exposure. Lesion may resolve spontaneously or progress into a lupus vulgaris like picture. Rarely, it may lead to disseminated tuberculosis.We report a case of primary inoculation tuberculosis of keloid presenting as cold abscess.

Keywords :

Lupus Vulgaris, Skin, Tuberculosis, Abscess, Keloid.

Article Options

FULL TEXT
ABSTRACT
PDF

PRINTER FRIENDLY VERSION

Search PubMed for

Search Google Scholar for

Article Statistics

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

Last updated on Jan 02, 2025